Corbus Pharmaceu Stock Price, News & Analysis

Corbus Pharmaceuticals (Nasdaq: CRBP) priced an underwritten public offering to raise approximately $75 million before underwriting discounts and expenses. The offering consists of 4,744,231 shares of common stock and pre-funded warrants to purchase 1,025,000 shares at $12.9999 each, with an exercise price of $0.0001 per share. Underwriters have a 30-day option for up to 865,384 additional shares. Closing is expected on or about November 3, 2025. Proceeds are intended to fund clinical development, working capital, and general corporate purposes.

Corbus Pharmaceuticals (Nasdaq: CRBP) announced on Oct 30, 2025 a proposed underwritten public offering of its common stock and, for certain investors, pre-funded warrants to purchase common stock. All securities will be sold by Corbus, and the offering is subject to market conditions with no assurance of completion, size, or terms.

Corbus said it intends to use net proceeds to fund clinical development of its pipeline and for working capital and general corporate purposes. Jefferies and Piper Sandler are joint book-running managers, and underwriters may receive a 30-day option to buy up to an additional 15% of the shares. A registration statement became effective on Mar 20, 2024.

Corbus Pharmaceuticals (NASDAQ: CRBP) reported Phase 1/2 CRB-701 (SYS6002) data presented at ESMO25 showing clinical activity and a manageable safety profile.

In response-evaluable patients dosed at 3.6 mg/kg, CRB-701 produced ORR 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in metastatic urothelial cancer. No dose-limiting toxicities were observed; Grade 3 treatment-related adverse events occurred in 18.0%, with no Grade 4/5 events and a 6.0% discontinuation rate. Data cutoff was September 1, 2025 (167 patients enrolled; 84 response-evaluable). The company plans an FDA meeting in 2025 and expects to initiate registrational studies by mid-2026.

Corbus Pharmaceuticals (NASDAQ: CRBP) will present updated Phase 1/2 data for CRB-701 (SYS6002) at ESMO 2025 on October 19, 2025 (Poster #967P) with a poster session from 12:00–12:45 CEST. The poster reports a September 1, 2025 data cut showing 167 enrolled participants, of which 122 were evaluable for efficacy across HNSCC (n=41), cervical (n=37), metastatic urothelial (n=23) and other dose-escalation tumors (n=21).

The abstract also includes safety data from an April 2025 cut on 70 participants. Corbus will host an in-person and virtual HNSCC KOL event in Berlin on October 19 at 10:00 CEST featuring HNSCC experts and a live Q&A.

Corbus Pharmaceuticals (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D. will participate in a Fireside Chat at the Piper Sandler Virtual Oncology Symposium on October 9-10, 2025. The Corbus session is scheduled for October 9, 2025 at 10:00AM ET and will be hosted by Biren Amin, Managing Director, Piper Sandler Healthcare Equity Research.

Piper Sandler clients can register through their representative. The participation is a presentation event and does not include new financial guidance or clinical readout details.

Corbus Pharmaceuticals (NASDAQ: CRBP) announced it will host a Key Opinion Leader (KOL) event at ESMO Congress 2025 in Berlin, Germany. The event will present dose optimization data from the Phase 1/2 clinical study of CRB-701 involving over 100 patients with head and neck squamous cell carcinoma (HNSCC), cervical, or metastatic urothelial tumors.

The KOL panel will feature prominent experts from leading institutions including the University of Chicago, Dana-Farber Cancer Institute, and Sarah Cannon Research Institute. The event is scheduled for October 19, 2025, at 10AM CEST, with both in-person and virtual attendance options available. The clinical trial data will also be presented as a poster at ESMO 2025.

Corbus Pharmaceuticals (NASDAQ: CRBP) has received Fast Track designation from the FDA for its antibody drug conjugate CRB-701 in treating recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). This marks the second Fast Track designation for CRB-701, following its December 2024 designation for relapsed/refractory metastatic cervical cancer.

CRB-701 is a next-generation Nectin-4 targeting ADC featuring a site-specific, cleavable linker and a precise drug antibody ratio of 2 using MMAE payload. The company is conducting a Phase 1/2 clinical trial evaluating CRB-701's safety, pharmacokinetics, and efficacy in advanced solid tumors with high Nectin-4 expression. Initial dose optimization data will be presented at ESMO 2025 on October 19, 2025.

Corbus Pharmaceuticals (NASDAQ: CRBP) has reported Q2 2025 financial results and provided updates on its three clinical programs. The company posted a net loss of $17.7 million ($1.44 per share) and holds $116.6 million in cash, sufficient to fund operations through Q2 2027.

Key developments include: CRB-701 (Nectin-4 targeting ADC) Phase 1/2 dose expansion data to be presented at ESMO 2025, with Fast Track designation for cervical cancer treatment; CRB-913 (obesity drug) has initiated its 7-day MAD study phase with SAD/MAD data expected later this year; and CRB-601 (anti-αvβ8 integrin mAB) is progressing with dose escalation data expected in Q4 2025.

Corbus Pharmaceuticals (NASDAQ: CRBP) announced the acceptance of their abstract for presentation at the ESMO Congress 2025 in Berlin. The presentation will showcase updated clinical data from their Phase 1/2 study of CRB-701, a next-generation Nectin-4-targeting antibody-drug conjugate.

The study (NCT06265727) is evaluating CRB-701 in patients with advanced solid tumors expressing Nectin-4. Part A evaluated four doses (1.8-4.5 mg/kg Q3W), with ongoing dose optimization in Part B at 2.7 and 3.6 mg/kg cohorts in HNSCC, cervical, and mUC tumors. The company expects to identify a recommended Phase 2 dose in Q4 2025.